Pantoprazole Tablet: Uses, Dose, Side Effects and Top Brands in India (2026)

• Updated 23 October 2026
• Reviewed by Sudhanshu Singhal
• 18 min read
• 39 sources

These MRPs are taken from Tata 1mg brand pages read on 23 October 2026, and 1mg itself states that MRP may vary by batch, so the price printed on the pack always governs. These are brands listed on 1mg for each form; they are not ranked by sales, and no published sales source was found.

What is pantoprazole?

Pantoprazole is a proton pump inhibitor, which is a class of medicine that reduces stomach acid by stopping the proton pumps in the stomach lining from working properly.

How it works in plain words

The NHS describes pantoprazole as "a type of medicine called a proton pump inhibitor (PPI)". The US FDA label states that it "suppresses the final step in gastric acid production by covalently binding to the (H+, K+)-ATPase enzyme system at the secretory surface of the gastric parietal cell", and that the acid-lowering effect lasts longer than 24 hours at every dose tested from 20 mg to 120 mg.

After the first 40 mg oral dose, a mean 51% inhibition of acid output was reached by 2.5 hours; after seven days of once-daily dosing the figure was 85%, and acid secretion returned to normal within a week of the last dose with no evidence of rebound hypersecretion. The NHS says most people start to feel better within 2 to 3 days, while the full effect can take up to 4 weeks.

Forms and strengths sold in India

Indian pharmacy listings show pantoprazole in these forms: the 40 mg tablet, the 40 mg injection, and fixed-dose combinations with domperidone (10 mg tablet, or 30 mg sustained-release capsule "DSR"), levosulpiride 75 mg SR and cinitapride 3 mg SR.

The tablet is a gastro-resistant tablet, which means the coating is made to survive stomach acid; the UK label says such tablets must be swallowed whole. The injection is a 40 mg vial for intravenous use, and the UK label for the injection says to switch to the tablet as soon as oral therapy is possible.

What each combination partner adds

• Domperidone is described in the UK product information as a dopamine antagonist with anti-emetic activity that does not readily cross the blood-brain barrier. Human studies show it increases lower oesophageal pressure, improves antroduodenal motility and speeds gastric emptying, with no effect on gastric secretion.
• Levosulpiride is called "the levorotatory enantiomer of sulpiride" in the J.B. Chemicals leaflet, a selective dopamine D2 receptor blocker in the upper gut and the chemoreceptor trigger zone, acting as a prokinetic with "a strong antiemetic effect". A peer-reviewed study describes it as a selective dopamine D2-receptor antagonist with prokinetic activity.
• Cinitapride is described in the Spanish label (Cidine, Almirall) as an orthopramide with gastrointestinal prokinetic activity and a marked procholinergic action, with a modest antidopaminergic action.

For the two products whose leaflets we could read, the capsule holds two pellet types: the Alkem PAN-D leaflet describes pantoprazole as enteric-coated pellets and domperidone 30 mg as sustained-release pellets, and the J.B. Panum L leaflet describes levosulpiride 75 mg as sustained-release pellets. A pharmaceutical explainer (secondary source) says sustained release, also called prolonged release, means the drug is released more slowly than from a plain tablet, while delayed release and gastro-resistant are different ideas, about surviving stomach acid rather than release speed.

What is it used for?

The US and UK labels, and the leaflets of the Indian manufacturers, list the uses of pantoprazole and its combinations; labels differ by country and by product, so the pack in your hand and your doctor's advice govern.

Pantoprazole alone

• US FDA label: short-term treatment (up to 8 weeks) of erosive oesophagitis associated with GERD in adults and children 5 years and older; maintenance of healing of erosive oesophagitis and reduction in relapse of daytime and night-time heartburn in adults with GERD; and long-term treatment of pathological hypersecretory conditions including Zollinger-Ellison syndrome.
• UK product information (40 mg tablets): reflux oesophagitis in adults and adolescents 12 and over; in adults, eradication of H. pylori with appropriate antibiotics in H. pylori-associated ulcers, gastric and duodenal ulcer, and Zollinger-Ellison syndrome with other pathological hypersecretory conditions.
• UK product information (40 mg injection): reflux oesophagitis, gastric and duodenal ulcer, and Zollinger-Ellison syndrome in adults; the label says to switch to the tablet as soon as oral therapy is possible.
• NHS: heartburn, acid reflux and gastro-oesophageal reflux disease (GORD), preventing and treating stomach ulcers, and sometimes Zollinger-Ellison syndrome.

The Indian combinations

The Alkem PAN-D leaflet (pantoprazole 40 mg + domperidone 30 mg) states the product is "indicated for the treatment of Gastroesophageal reflux disease (GERD)". The J.B. Chemicals Panum L leaflet (pantoprazole 40 mg + levosulpiride 75 mg) states "For short term treatment of GERD in adult patients who do not respond to PPI alone." Cinitapride's own Spanish label covers mild-to-moderate dysmotility-type dyspepsia and use as an addition in gastro-oesophageal reflux when proton pump inhibitors alone have been insufficient.

No Indian prescribing leaflet was found for the pantoprazole + cinitapride 3 mg capsule or the pantoprazole + domperidone 10 mg tablet, so the two single-ingredient labels are the reference for those. These are prescription medicines and must be taken only as prescribed by a doctor.

Dose as stated in the labels

Every label gives its own regimen, and the pack in the patient's hand governs; the doses below are the usual adult doses stated in the labels, and they are not personal instructions.

Pantoprazole tablets

The US FDA label states: erosive oesophagitis with GERD, usual adult dose 40 mg once daily for up to 8 weeks (a further 8-week course may be considered if not healed); children 5 years and over, 20 mg once daily for body weight 15 kg to under 40 kg and 40 mg once daily at 40 kg and above, up to 8 weeks; maintenance of healing, usual adult dose 40 mg once daily; Zollinger-Ellison and similar conditions, usual adult dose 40 mg twice daily, adjusted to need. Tablets are swallowed whole, with or without food, and must not be split, chewed or crushed.

The UK product information states: reflux oesophagitis one tablet daily (which may be doubled in individual cases), usually 4 weeks and up to a further 4 weeks; gastric ulcer the same; duodenal ulcer usually heals in 2 weeks, up to a further 2 weeks; H. pylori eradication one tablet twice daily with two antibiotics, generally 7 days and up to 14 days; Zollinger-Ellison starts at 80 mg daily and is then titrated. The UK label says the tablet is swallowed whole with some water one hour before a meal. Note that the UK and US labels differ on food timing, so follow the pack you have and your doctor's advice.

The NHS describes adult doses of 20 mg to 40 mg a day depending on the condition, usually once a day first thing in the morning, best taken an hour before a meal. The NHS also states that a pharmacy supply is usually up to 2 weeks, and not more than 4 weeks without speaking to a doctor.

Pantoprazole 40 mg injection

The UK product information states one 40 mg vial a day for gastric or duodenal ulcer and reflux oesophagitis, and 80 mg daily to start for Zollinger-Ellison syndrome, given intravenously over 2 to 15 minutes, with intravenous data covering up to 7 days. In severe liver impairment the daily dose is not to exceed 20 mg, and the injection is not recommended under 18 years.

The combinations

• Alkem PAN-D (pantoprazole 40 mg + domperidone 30 mg): "One capsule once daily preferably before meal."
• J.B. Panum L (pantoprazole 40 mg + levosulpiride 75 mg): once daily or as directed by the physician, swallowed whole one hour before a meal with some water.
• Cinitapride's own label (Spain): adults over 20 years, one 1 mg tablet three times daily 15 minutes before each meal. No dose line is available from any leaflet for the 3 mg cinitapride capsule, so none is given here.

Domperidone alone, per the UK product information, is 10 mg up to three times daily for adults and adolescents 12 years and over weighing 35 kg or more, taken 15 to 30 minutes before meals, with a usual maximum treatment duration of one week. Always take these medicines exactly as prescribed by your doctor.

Side effects

The most common side effects in the FDA adult trials were headache, diarrhoea and nausea, and the labels also warn about a set of serious reactions whose individual frequencies are not always stated.

Common side effects

From the FDA Table 3 in adult GERD trials, the rates on pantoprazole were headache 12.2%, diarrhoea 8.8%, nausea 7.0%, abdominal pain 6.2%, vomiting 4.3%, flatulence 3.9%, dizziness 3.0% and joint pain 2.8%; the placebo columns for the same events were 8.5%, 4.9%, 9.8%, 6.1%, 2.4%, 3.7%, 1.2% and 1.2%, so trial rates are not all caused by the drug. The NHS says most people who take pantoprazole do not have any side effects; those affecting fewer than 1 in 100 people include headaches, diarrhoea, nausea or vomiting, constipation, dry mouth and tiredness.

Serious effects the labels warn about

• Severe skin reactions (SJS, TEN, DRESS, AGEP), cutaneous and systemic lupus, and acute tubulointerstitial nephritis.
• Clostridium difficile-associated diarrhoea, and a slightly higher risk of Salmonella, Campylobacter and C. difficile infection.
• Low magnesium with long use (tetany, arrhythmias, seizures), vitamin B12 deficiency with daily acid suppression longer than 3 years, and a modest rise in hip, wrist and spine fracture risk with high doses for a year or longer.
• Fundic gland polyps (risk rises especially beyond one year), and the masking of gastric malignancy when symptoms respond.

The UK product information for pantoprazole tablets says about 5% of patients can be expected to experience adverse drug reactions, and the NHS says most people have none. The NHS lists the rarer reactions (under 1 in 1,000) as a lupus-type rash with joint pain, liver problems, kidney problems and severe persistent diarrhoea, and says blood magnesium may fall after more than 3 months and that a doctor should review use beyond one year. The UK label says to withdraw treatment at once if a severe cutaneous reaction appears.

Domperidone carries a cardiac warning: the European review found a small increased risk of QT prolongation, torsade de pointes, serious ventricular arrhythmia and sudden cardiac death, higher in people over 60 and in adults taking more than 30 mg a day. The DSR capsules sold in India contain 30 mg of domperidone as sustained-release pellets, taken once a day per the leaflets. Levosulpiride may cause raised prolactin with prolonged use, and cinitapride's label lists somnolence as uncommon.

Who should not take it, and interactions

Pantoprazole must not be used by anyone with known hypersensitivity to pantoprazole or substituted benzimidazoles, and it is contraindicated with rilpivirine-containing products; domperidone and the other combination partners add their own contraindications.

Contraindications

• Pantoprazole: hypersensitivity to the drug, substituted benzimidazoles or excipients; rilpivirine products (FDA). The UK label adds that it must not be used in H. pylori combination therapy in moderate to severe hepatic dysfunction or impaired renal function.
• Domperidone: prolactin-releasing pituitary tumour, phaeochromocytoma, gastrointestinal bleeding, obstruction or perforation, moderate or severe liver impairment, known QT prolongation, significant electrolyte disturbance, underlying cardiac disease such as heart failure, and co-administration with QT-prolonging drugs or potent CYP3A4 inhibitors.
• Levosulpiride: hypersensitivity, phaeochromocytoma, epilepsy, manic states, prolactin-dependent tumours, and pregnancy and lactation; it must not be used where gut stimulation could be harmful.
• Cinitapride: bleeding, obstruction or perforation, and proven neuroleptic tardive dyskinesia.

Key interactions

With pantoprazole, atazanavir and nelfinavir exposure falls, saquinavir exposure rises, warfarin needs INR monitoring, high-dose methotrexate levels may rise, and drugs that need stomach acid to be absorbed (iron salts, ketoconazole, itraconazole, erlotinib, mycophenolate) may be absorbed less; clopidogrel needs no dose adjustment. With domperidone, ketoconazole and erythromycin raise its levels and the QT interval, and antacids and antisecretory agents lower its absorption, so the labels say to take domperidone before meals and those medicines after meals.

Pregnancy, breastfeeding and alcohol

The UK label for pantoprazole says data on 300 to 1,000 pregnancy outcomes show no malformation or foetal toxicity, but as a precaution it is preferable to avoid use in pregnancy; the NHS says it is not usually recommended. For breastfeeding, the NHS says tiny amounts reach the milk, while the UK label says a risk to the newborn cannot be excluded. Levosulpiride is contraindicated in pregnancy and lactation per the J.B. leaflet, and the cinitapride label advises avoiding it as a precaution. The J.B. leaflet warns about caution with alcohol, and the cinitapride label notes sedation with alcohol.

Rules in India

Pantoprazole and domperidone are Schedule H prescription drugs under the Drugs and Cosmetics Rules, 1945, and pantoprazole injection 40 mg is on NLEM 2022 with a price ceiling noted by a secondary price-tracking service.

• Schedule H: the rules text lists Domperidone (item 161), Pantoprazole (item 386) and Sulpiride (item 475) as prescription drugs. Levosulpiride and cinitapride are not named in that text, which is as amended up to 30 September 2020.
• NLEM 2022 (Gazette of India, S.O. 5249(E), 11 November 2022): Pantoprazole is listed at levels S and T in "Injection 40 mg" only, so the pantoprazole tablet is not on the list; Domperidone is listed at P, S and T in tablet 10 mg and oral liquid 1 mg/mL. No levosulpiride, cinitapride or combination is listed.
• NPPA ceiling price (secondary source, not verified against the gazette order): a price-tracking service that reads NPPA data lists the ceiling for pantoprazole injection 40 mg at ₹51.66 per vial and for domperidone tablet 10 mg at ₹2.37 per tablet under S.O. 1575(E) dated 25 March 2026. No ceiling price is listed there for the pantoprazole tablet or for any pantoprazole combination, consistent with those not being on NLEM.

Every brand page on 1mg that we read carries a "Prescription required" note. Pantoprazole and its combinations should be taken only as prescribed by a doctor.

Top brands in India

The table at the top of this page lists brands that appear on Tata 1mg for each form of pantoprazole sold in India, along with their marketers, common packs and MRPs as read on 23 October 2026; this is a list for information and not a ranking, because no published sales source was found.

The Vibcare range

Vibcare Pharma supplies pantoprazole 40 mg tablets and injections, and fixed-dose combinations with domperidone 10 mg and 30 mg, levosulpiride 75 mg and cinitapride 3 mg, across brands such as Pantalam, Pantavib, Pantojem and Panunor. The tablets and capsules come in Alu Alu packs of 10x10 and 10x15, and the injections are supplied as single (1's) packs.

This range is available to Vibcare PCD franchise partners with monopoly rights in their district; see our Gastro PCD franchise and PCD pharma franchise pages for details.

Frequently asked questions

Sources

Related reading

• Rabeprazole: uses, dose and brands
• Antacid syrup: types, uses and brands
• Gastro PCD franchise with Vibcare
• PCD pharma franchise with Vibcare
• Browse the Vibcare product range